Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Dec;41(12):1250-5.
doi: 10.1016/j.exger.2006.10.010. Epub 2006 Nov 27.

Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly

Alejandro Diaz-Borjon  1 , Cornelia M Weyand, Jörg J Goronzy
Affiliations
Review

Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly

Alejandro Diaz-Borjon et al. Exp Gerontol. 2006 Dec.

Abstract

The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population.

PubMed Disclaimer

References

    1. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, Lavayssiere L, Oksman F, Dur D, Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation. 2005;80:1560–1564. - PubMed
    1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama. 2006;295:2275–2285. - PubMed
    1. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37. - PubMed
    1. Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol. 2006;33:1197–1198. - PubMed
    1. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(Suppl 2):ii18–ii24. - PMC - PubMed

Publication types

MeSH terms